Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma, Kaposi | 14 | 2023 | 120 | 6.170 |
Why?
|
Epstein-Barr Virus Infections | 11 | 2024 | 292 | 3.530 |
Why?
|
HIV Infections | 16 | 2023 | 1896 | 2.380 |
Why?
|
Burkitt Lymphoma | 9 | 2024 | 144 | 2.310 |
Why?
|
Herpesvirus 4, Human | 9 | 2024 | 674 | 2.210 |
Why?
|
Herpesvirus 8, Human | 3 | 2023 | 49 | 1.670 |
Why?
|
Lymphoma | 4 | 2023 | 324 | 1.580 |
Why?
|
Malawi | 17 | 2025 | 396 | 1.390 |
Why?
|
Lymphoproliferative Disorders | 5 | 2024 | 224 | 1.250 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2023 | 164 | 1.240 |
Why?
|
Histiocytosis, Langerhans-Cell | 4 | 2024 | 225 | 1.230 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 145 | 1.230 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2025 | 15 | 0.960 |
Why?
|
Child | 41 | 2025 | 24462 | 0.940 |
Why?
|
Organ Transplantation | 2 | 2024 | 165 | 0.930 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 143 | 0.820 |
Why?
|
Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.820 |
Why?
|
Lymphoma, T-Cell | 4 | 2021 | 65 | 0.750 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 1237 | 0.700 |
Why?
|
Adolescent | 27 | 2025 | 19331 | 0.680 |
Why?
|
Interleukin-6 | 2 | 2019 | 421 | 0.670 |
Why?
|
Disease Susceptibility | 1 | 2021 | 296 | 0.660 |
Why?
|
Anemia | 2 | 2023 | 340 | 0.640 |
Why?
|
Viral Load | 4 | 2018 | 385 | 0.610 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2020 | 269 | 0.590 |
Why?
|
Cytokines | 3 | 2021 | 1290 | 0.580 |
Why?
|
Herpesviridae Infections | 1 | 2018 | 142 | 0.570 |
Why?
|
Humans | 53 | 2025 | 124809 | 0.520 |
Why?
|
Vincristine | 5 | 2020 | 195 | 0.520 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 1668 | 0.450 |
Why?
|
Lymphoma, B-Cell | 2 | 2025 | 142 | 0.420 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2025 | 1196 | 0.390 |
Why?
|
Rituximab | 3 | 2024 | 157 | 0.390 |
Why?
|
Child, Preschool | 16 | 2025 | 14054 | 0.390 |
Why?
|
Neoplasms | 4 | 2025 | 2789 | 0.380 |
Why?
|
Methotrexate | 3 | 2025 | 341 | 0.380 |
Why?
|
Hydroa Vacciniforme | 1 | 2010 | 3 | 0.350 |
Why?
|
Male | 27 | 2025 | 61306 | 0.330 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2020 | 136 | 0.320 |
Why?
|
Disease Management | 2 | 2025 | 521 | 0.320 |
Why?
|
Young Adult | 12 | 2024 | 8991 | 0.310 |
Why?
|
Female | 27 | 2025 | 66575 | 0.310 |
Why?
|
Tanzania | 3 | 2023 | 68 | 0.290 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2010 | 501 | 0.280 |
Why?
|
Prognosis | 6 | 2025 | 4615 | 0.280 |
Why?
|
Bone Marrow | 3 | 2021 | 325 | 0.270 |
Why?
|
Neoplasm Staging | 3 | 2019 | 1228 | 0.260 |
Why?
|
Immunotherapy | 4 | 2022 | 665 | 0.260 |
Why?
|
Prospective Studies | 8 | 2025 | 6138 | 0.260 |
Why?
|
Retrospective Studies | 9 | 2025 | 16294 | 0.250 |
Why?
|
Laboratories, Hospital | 1 | 2025 | 21 | 0.240 |
Why?
|
Skin Neoplasms | 3 | 2023 | 806 | 0.240 |
Why?
|
Infant | 9 | 2025 | 12488 | 0.240 |
Why?
|
Doxorubicin | 3 | 2020 | 298 | 0.220 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 872 | 0.220 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2025 | 181 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 173 | 0.210 |
Why?
|
Lymphomatoid Papulosis | 1 | 2023 | 3 | 0.210 |
Why?
|
Cyclophosphamide | 3 | 2020 | 422 | 0.210 |
Why?
|
Mycosis Fungoides | 1 | 2023 | 15 | 0.210 |
Why?
|
Treatment Outcome | 11 | 2025 | 12341 | 0.210 |
Why?
|
HIV-1 | 2 | 2016 | 467 | 0.200 |
Why?
|
Adult | 9 | 2024 | 29482 | 0.200 |
Why?
|
Mucositis | 1 | 2022 | 18 | 0.200 |
Why?
|
Morbidity | 1 | 2023 | 244 | 0.200 |
Why?
|
Haploinsufficiency | 1 | 2024 | 257 | 0.200 |
Why?
|
Africa South of the Sahara | 2 | 2020 | 115 | 0.200 |
Why?
|
MAP Kinase Signaling System | 1 | 2024 | 316 | 0.200 |
Why?
|
Molecular Targeted Therapy | 2 | 2015 | 354 | 0.200 |
Why?
|
Translocation, Genetic | 1 | 2024 | 356 | 0.190 |
Why?
|
Medical Oncology | 1 | 2023 | 213 | 0.190 |
Why?
|
Perforin | 1 | 2021 | 17 | 0.190 |
Why?
|
Killer Cells, Natural | 2 | 2021 | 324 | 0.180 |
Why?
|
Virus Replication | 1 | 2023 | 611 | 0.170 |
Why?
|
Cysticercosis | 1 | 2020 | 21 | 0.170 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 195 | 0.170 |
Why?
|
Bleomycin | 2 | 2020 | 150 | 0.170 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2020 | 61 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 530 | 0.170 |
Why?
|
Lymphadenopathy | 1 | 2019 | 29 | 0.160 |
Why?
|
Anthracyclines | 2 | 2017 | 36 | 0.160 |
Why?
|
Tertiary Healthcare | 1 | 2019 | 21 | 0.160 |
Why?
|
Clinical Decision-Making | 1 | 2021 | 267 | 0.160 |
Why?
|
Endemic Diseases | 1 | 2018 | 57 | 0.150 |
Why?
|
HIV Protease Inhibitors | 1 | 2018 | 54 | 0.150 |
Why?
|
Anti-HIV Agents | 2 | 2020 | 315 | 0.150 |
Why?
|
Virus Activation | 1 | 2018 | 87 | 0.150 |
Why?
|
Biopsy | 1 | 2021 | 1239 | 0.140 |
Why?
|
Withholding Treatment | 1 | 2017 | 68 | 0.140 |
Why?
|
Hodgkin Disease | 2 | 2017 | 293 | 0.140 |
Why?
|
Asia | 1 | 2017 | 107 | 0.140 |
Why?
|
Plasma | 1 | 2017 | 98 | 0.130 |
Why?
|
Europe | 1 | 2017 | 354 | 0.130 |
Why?
|
HIV | 1 | 2017 | 180 | 0.130 |
Why?
|
Risk | 1 | 2017 | 757 | 0.120 |
Why?
|
Developing Countries | 1 | 2017 | 269 | 0.120 |
Why?
|
Remission Induction | 1 | 2016 | 302 | 0.120 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 3447 | 0.120 |
Why?
|
Angiomatosis, Bacillary | 1 | 2014 | 3 | 0.120 |
Why?
|
Algorithms | 1 | 2021 | 1616 | 0.110 |
Why?
|
Risk Factors | 4 | 2023 | 10274 | 0.110 |
Why?
|
Pilot Projects | 1 | 2018 | 1402 | 0.110 |
Why?
|
T-Lymphocytes | 3 | 2019 | 1709 | 0.110 |
Why?
|
Mass Spectrometry | 1 | 2014 | 331 | 0.110 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 170 | 0.100 |
Why?
|
Child Health Services | 1 | 2013 | 87 | 0.100 |
Why?
|
Biomarkers | 1 | 2021 | 3063 | 0.100 |
Why?
|
Adenoviridae Infections | 1 | 2011 | 70 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 1135 | 0.090 |
Why?
|
Proteomics | 1 | 2014 | 500 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2013 | 224 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 3143 | 0.090 |
Why?
|
Recurrence | 2 | 2024 | 1427 | 0.090 |
Why?
|
Survival Rate | 4 | 2017 | 2036 | 0.080 |
Why?
|
United States | 2 | 2023 | 10875 | 0.080 |
Why?
|
Infant, Newborn | 2 | 2025 | 8189 | 0.080 |
Why?
|
DNA, Viral | 3 | 2017 | 480 | 0.080 |
Why?
|
Genomics | 1 | 2017 | 1490 | 0.080 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 1090 | 0.080 |
Why?
|
Transcriptome | 1 | 2014 | 940 | 0.080 |
Why?
|
Diagnosis, Differential | 2 | 2024 | 1894 | 0.070 |
Why?
|
Mutation | 1 | 2021 | 5815 | 0.070 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 779 | 0.070 |
Why?
|
Cell Line, Tumor | 1 | 2014 | 3342 | 0.070 |
Why?
|
Cell Proliferation | 1 | 2014 | 2307 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2025 | 5155 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 2 | 2018 | 232 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2014 | 1929 | 0.070 |
Why?
|
Prednisone | 2 | 2019 | 275 | 0.070 |
Why?
|
Time Factors | 1 | 2016 | 6312 | 0.060 |
Why?
|
Signal Transduction | 1 | 2017 | 4542 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2016 | 868 | 0.060 |
Why?
|
Lymph Nodes | 2 | 2019 | 380 | 0.060 |
Why?
|
Adenine Nucleotides | 1 | 2024 | 41 | 0.060 |
Why?
|
Arabinonucleosides | 1 | 2024 | 32 | 0.060 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2024 | 78 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2025 | 170 | 0.050 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2024 | 100 | 0.050 |
Why?
|
Hyperplasia | 1 | 2024 | 208 | 0.050 |
Why?
|
Biomarkers, Tumor | 2 | 2024 | 1473 | 0.050 |
Why?
|
DNA Helicases | 1 | 2024 | 227 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2024 | 194 | 0.050 |
Why?
|
Transplantation, Autologous | 1 | 2022 | 298 | 0.050 |
Why?
|
Seroepidemiologic Studies | 1 | 2021 | 121 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2022 | 236 | 0.040 |
Why?
|
Creatinine | 1 | 2022 | 389 | 0.040 |
Why?
|
Transplantation Conditioning | 1 | 2022 | 324 | 0.040 |
Why?
|
Chromatin | 1 | 2024 | 555 | 0.040 |
Why?
|
Anticestodal Agents | 1 | 2020 | 3 | 0.040 |
Why?
|
Praziquantel | 1 | 2020 | 11 | 0.040 |
Why?
|
Subcutaneous Tissue | 1 | 2020 | 15 | 0.040 |
Why?
|
Taenia solium | 1 | 2020 | 11 | 0.040 |
Why?
|
Autoimmunity | 1 | 2021 | 173 | 0.040 |
Why?
|
Immunity | 1 | 2021 | 189 | 0.040 |
Why?
|
Albendazole | 1 | 2020 | 29 | 0.040 |
Why?
|
Paclitaxel | 1 | 2020 | 125 | 0.040 |
Why?
|
Middle Aged | 4 | 2024 | 26727 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2020 | 235 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2020 | 296 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2021 | 777 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2024 | 1272 | 0.040 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 141 | 0.040 |
Why?
|
Proto-Oncogenes | 1 | 2017 | 37 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 1161 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2017 | 128 | 0.030 |
Why?
|
Viremia | 1 | 2016 | 128 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 449 | 0.030 |
Why?
|
Genetic Testing | 1 | 2021 | 1004 | 0.030 |
Why?
|
Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 3 | 0.030 |
Why?
|
Antigens, CD20 | 1 | 2014 | 37 | 0.030 |
Why?
|
Risk Assessment | 2 | 2016 | 3436 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 63 | 0.030 |
Why?
|
Transcription Factors | 1 | 2024 | 2609 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2016 | 197 | 0.030 |
Why?
|
Antigens, CD19 | 1 | 2014 | 177 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 1351 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2014 | 237 | 0.030 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
Botswana | 1 | 2013 | 76 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2016 | 1328 | 0.030 |
Why?
|
Child Nutrition Disorders | 1 | 2013 | 75 | 0.030 |
Why?
|
Gene Expression | 1 | 2017 | 1569 | 0.020 |
Why?
|
Mouth Neoplasms | 1 | 2013 | 84 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2017 | 607 | 0.020 |
Why?
|
Sex Factors | 1 | 2016 | 1285 | 0.020 |
Why?
|
Liver | 1 | 2019 | 1764 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 768 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2013 | 227 | 0.020 |
Why?
|
Animals | 2 | 2024 | 34188 | 0.020 |
Why?
|
Incidence | 1 | 2018 | 3144 | 0.020 |
Why?
|
Japan | 1 | 2011 | 133 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2014 | 482 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 1699 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 661 | 0.020 |
Why?
|
Cell Separation | 1 | 2010 | 229 | 0.020 |
Why?
|
Age Factors | 1 | 2016 | 2820 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 1028 | 0.020 |
Why?
|
RNA, Viral | 1 | 2011 | 541 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 1019 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 764 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2011 | 531 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2010 | 803 | 0.020 |
Why?
|
Pregnancy | 1 | 2020 | 7172 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 1248 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2011 | 541 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 1588 | 0.020 |
Why?
|
Mice | 1 | 2024 | 17743 | 0.020 |
Why?
|
Chronic Disease | 1 | 2011 | 1192 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2010 | 1691 | 0.020 |
Why?
|
Aged | 1 | 2024 | 19693 | 0.020 |
Why?
|